<DOC>
	<DOCNO>NCT00646425</DOCNO>
	<brief_summary>The objective trial ass treatment basiliximab allow subject taper immunosuppressive drug regimen without cause increase uveitis .</brief_summary>
	<brief_title>The Safety Efficacy Basiliximab Maintenance Therapy Subjects With Stable , Noninfectious Uveitis</brief_title>
	<detailed_description />
	<mesh_term>Uveitis</mesh_term>
	<mesh_term>Basiliximab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Diagnosis noninfectious intermediate , posterior panuveitis least 3 month duration Treatment great equal 20 mg/day Prednisone baseline immunosuppressive drug score great equal 5 baseline BCVA ETDRS protocol well equal 20/200 Intraocular pressure 24 mmHg less Anterior chamber cell vitreous haze less equal 1 Male female , age 12 great , body weight 40 kg great Prior treatment Retisert Primary diagnosis anterior uveitis , uveitis infectious etiology Behcet 's disease Pregnancy breastfeed Increase systemic immunosuppressive treatment regimen within 6 week baseline</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>Non-infectious uveitis</keyword>
</DOC>